Table 4. CSF Biomarker Concentrations in Relation to Ongoing Medical Treatments (Separate Linear Regression with Age and Gender as Covariates).
NF-La |
MBP |
S100B |
H-FABP |
|||||
---|---|---|---|---|---|---|---|---|
β | P | β | P | β | P | β | P | |
Lithium | 0.015 | 0.865 | −0.083 | 0.345 | 0.016 | 0.860 | 0.177 | 0.043 |
Divalproex | 0.046 | 0.599 | 0.094 | 0.283 | −0.075 | 0.395 | −0.143 | 0.103 |
Lamotrigine | 0.064 | 0.469 | 0.268 | 0.002 | 0.081 | 0.357 | 0.066 | 0.452 |
Antidepressants | −0.025 | 0.775 | 0.010 | 0.911 | −0.019 | 0.825 | −0.039 | 0.660 |
Anxiolytics | 0.074 | 0.400 | 0.119 | 0.174 | 0.022 | 0.806 | 0.076 | 0.387 |
Atypical antipsychotics | 0.206 | 0.018 | 0.066 | 0.454 | 0.114 | 0.194 | 0.075 | 0.396 |
Abbreviations: NF-L, neurofilament light chain; MBP, myelin basic protein; S100B, calcium-binding protein S100B; h-FABP, heart-type fatty acid binding protein.
Log transformed before statistical analysis.